Background: According to internationally published data, 35.2–64.4% of breast cancer cases are with HER2-low expression (Gampenrieder et al., 2021; Miglietta et al., 2021; Horishawa et al., 2021) out of all the breast cancer cases with identified HER2 expression (HER2 0, HER2 1+, HER2 2+, HER2 3+). This study aimed to determine HER2-low breast cancer epidemiology data in Lithuania and compare it with officially published data from clinical trials and epidemiologic studies.
Z Klippel合作论文数1T Sálek合作论文数1Reiner Maureen合作论文数1O'Reilly Seamus合作论文数1Decaestecker Jochen合作论文数1
Hotko Yevhen合作论文数1
Phuong Khanh (P.K.) Morrow合作论文数Oncology Therapeutic Area Unit, Takeda Pharmaceuticals U.S.A., Inc.1Galina P. Kurteva合作论文数1
Jacek Jassem合作论文数Department of Oncology and Radiotherapy, Medical University of Gdańsk1
Charles D. Blanke合作论文数Knight Cancer Institute, Oregon Health & Science University;School of Medicine, Oregon Health & Science University1Adina Croitoru合作论文数Department of Oncology, Fundeni Clinical Institute1Lina Poskiene合作论文数1
Peter Gibbs合作论文数The Walter and Eliza Hall Institute of Medical Research1T. Pinter合作论文数Dr Jozsef Baka Diagnost Radiat Oncol Res & Teachi, Moritz Kaposi Teaching Hosp1
